Teaching harm reduction in vulnerable environments (THRIVE): a peer-led intervention bridging acute care settings and the discharge to the community

教导在脆弱环境中减少伤害(THRIVE):由同伴主导的干预措施,将急症护理环境与出院到社区联系起来

基本信息

项目摘要

ABSTRACT People who use drugs (PWUD) with acute medical problems have high rates of subsequent mortality and morbidity related to substance use, with notable racial disparities. While harm reduction services to reduce overdose and injection-related complications have historically functioned outside of health care settings, integrating harm reduction into acute care clinical settings could improve these outcomes. There is a critical gap in how best to implement harm reduction services in the health system that will lead to effective behavioral change and address equity gaps. Our study proposes to develop an acceptable, feasible, and effective peer-led bundle of harm reduction services. Our overall objectives are to tailor the THRIVE (Teaching Harm Reduction In Vulnerable Environments) intervention and determine its efficacy in changing behaviors and reducing health risks among PWUD. The THRIVE intervention was conceptualized by our team along with people with lived experience and informed by the COM-B model for Behavior Change and the Theoretical Domains Framework. THRIVE bundles evidence-based harm reduction strategies (e.g. safer injection education, take home naloxone, and fentanyl test strips). It includes a face-to-face session boosted by weekly text messages and electronic content. Content is delivered over 12 weeks. Our research team has the extensive expertise in community-partnered research, qualitative methodology, behavioral health intervention design, and clinical trial management needed to successfully complete the proposed aims. We will use a human-centered design approach to tailor the THRIVE model and address the patient, provider, and systems-level barriers to implementation in hospital and emergency-department settings. This includes a “Design Sprint” in which PWUD will map the problem (guided by qualitative interviews with patients and healthcare providers), sketch implementation elements, choose the key aspects to develop, and build model components. These implementation methods for the THRIVE model will then be user-tested with 20 patients over an 8-week period. We will then examine the efficacy of the THRIVE intervention in reducing the cumulative incidence of self-reported non-fatal overdose or skin and soft tissue infection between baseline and 6-months among PWUD in a hybrid type 1 randomized controlled trial. We will conduct a randomized controlled trial recruiting patients (n=390) admitted to the hospital or Emergency Department with opioid use disorder in one of three hospitals. We will also analyze implementation barriers and facilitators of the THRIVE model using the health equity implementation framework to identify any needed implementation supports for widescale implementation.
抽象的 患有严重医疗问题的吸毒者 (PWUD) 随后的死亡率和死亡率都很高 与药物使用相关的发病率存在显着的种族差异。同时减少伤害服务可以减少 药物过量和注射相关并发症历来在医疗机构之外发生过, 将减少伤害纳入急症护理临床环境可以改善这些结果。有一个关键的 在如何最好地在卫生系统中实施减少伤害服务方面存在差距,这将导致有效的行为 改变并解决公平差距。我们的研究建议制定一个可接受的、可行的、有效的、同行主导的 减少危害服务的捆绑包。我们的总体目标是定制 THRIVE(减少教学危害) 在脆弱环境中)干预并确定其在改变行为和减少行为方面的功效 残疾人士的健康风险。 THRIVE 干预措施是由我们的团队与患有以下疾病的人一起构思的 生活经验并通过行为改变和理论领域的 COM-B 模型获得信息 框架。 THRIVE 捆绑了基于证据的减害策略(例如更安全的注射教育、采取 家用纳洛酮和芬太尼试纸)。它包括每周一次的短信和面对面的会议 电子内容。内容在 12 周内交付。我们的研究团队拥有丰富的专业知识 社区合作研究、定性方法、行为健康干预设计和临床 成功完成拟议目标所需的试验管理。我们将采用以人为本的设计 定制 THRIVE 模型并解决患者、提供者和系统层面障碍的方法 在医院和急诊室环境中实施。这包括“设计冲刺”,其中 PWUD 将绘制问题地图(以与患者和医疗保健提供者进行定性访谈为指导),绘制草图 实施元素,选择要开发的关键方面,并构建模型组件。这些 THRIVE 模型的实施方法将在 8 周内对 20 名患者进行用户测试 时期。然后,我们将检查 THRIVE 干预措施在降低累积发生率方面的功效 基线至 6 个月期间自我报告的非致命性用药过量或皮肤和软组织感染 混合 1 型随机对照试验中的 PWUD。我们将进行随机对照试验招募 因以下三种情况之一因阿片类药物使用障碍入院或急诊科的患者 (n=390) 医院。我们还将利用健康状况分析 THRIVE 模型的实施障碍和促进因素 公平实施框架,以确定大规模实施所需的任何实施支持 执行。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacqueline Deanna Wilson其他文献

Jacqueline Deanna Wilson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jacqueline Deanna Wilson', 18)}}的其他基金

Treatment of Opioid Use Disorder in Young Adults Hospitalized with Infectious Complications of Injection Opioid Use
因注射阿片类药物使用引起感染性并发症而住院的年轻人阿片类药物使用障碍的治疗
  • 批准号:
    10834850
  • 财政年份:
    2023
  • 资助金额:
    $ 4.96万
  • 项目类别:
Teaching harm reduction in vulnerable environments (THRIVE): a peer-led intervention bridging acute care settings and the discharge to the community
教导在脆弱环境中减少伤害(THRIVE):由同伴主导的干预措施,将急症护理环境与出院到社区联系起来
  • 批准号:
    10834851
  • 财政年份:
    2022
  • 资助金额:
    $ 4.96万
  • 项目类别:
Treatment of Opioid Use Disorder in Young Adults Hospitalized with Infectious Complications of Injection Opioid Use
因注射阿片类药物使用引起感染性并发症而住院的年轻人阿片类药物使用障碍的治疗
  • 批准号:
    10053965
  • 财政年份:
    2020
  • 资助金额:
    $ 4.96万
  • 项目类别:
Treatment of Opioid Use Disorder in Young Adults Hospitalized with Infectious Complications of Injection Opioid Use
因注射阿片类药物使用引起感染性并发症而住院的年轻人阿片类药物使用障碍的治疗
  • 批准号:
    10424528
  • 财政年份:
    2020
  • 资助金额:
    $ 4.96万
  • 项目类别:
Treatment of Opioid Use Disorder in Young Adults Hospitalized with Infectious Complications of Injection Opioid Use
因注射阿片类药物使用引起感染性并发症而住院的年轻人阿片类药物使用障碍的治疗
  • 批准号:
    10197083
  • 财政年份:
    2020
  • 资助金额:
    $ 4.96万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 4.96万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了